Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma

(MedPage Today) -- NEW ORLEANS--Results of a large randomized trial support the inclusion of ibrutinib (Imbruvica) to the standard first-line treatment of younger patients with mantle cell lymphoma (MCL), a researcher reported here.
In the...